A parkinson-like neurologic deficit in primates is caused by a novel 4-substituted piperidine

Add time:08/20/2019    Source:sciencedirect.com

A neurologic deficit characterized by hypokinesia, postural flexion, and to a lesser extent, rigidity, tremor and myoclonus, has been observed in cynomolgus monkeys following administration of 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol (MMPP), a novel 4-substituted piperdine. The syndrome, similar to that described for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), developed within 3–7 days after oral or i.v. dosing, and was accompanied by lesions in the substantia nigra. The behavioral syndrome was seen to a lesser extent in dogs but not in rats. MMPP contains a hydroxyl group on the 4-position of the pyridine ring; the corresponding dehydration product was inactive.

We also recommend Trading Suppliers and Manufacturers of 4-Piperidinol,1-methyl- (cas 106-52-5). Pls Click Website Link as below: cas 106-52-5 suppliers

Prev:Studies of the elimination of 4-aryl-3-methyl-4-piperidinols—I : The conformation of epimeric 1-alkyl (and aralkyl)-4-aryl-5-methyl-1,2,5-6-tetrahydropyridine hydrochlorides
Next:3-Triphenylphosphonio-2,5-Piperazinedione (cas 106-57-0)s as new chiral glycine cation equivalents)